Compare iShares International Treasury Bond ETF (IGOV) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares International Treasury Bond ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? iShares International Treasury Bond ETF trades at $39.75 (market cap $1.30B), while Vertex Pharmaceuticals Incorporated trades at $513.16 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 98.1× iShares International Treasury Bond ETF's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, iShares International Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares International Treasury Bond ETF for 92 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| IGOV | VRTX | |
|---|---|---|
Market Cap | $1.30B | $127.55B |
Volume | 693,740 | 1,487,944 |
Sector | Fixed Income | Health |
52-Week High | $42.99 | $557.96 |
52-Week Low | $39.65 | $407.37 |
Typical Hold Time | 92 Days | 120 Days |
Enterprise Value | — | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IGOV trades at $39.70, down 0.48% with a bearish technical outlook as moving averages signal selling pressure. Key financial ratios including P/E, P/S, and ROE are unavailable, limiting fundamental assessment. Recent news highlights rising global bond yields, which may impact interest-rate sensitive sectors. The stock shows neutral oscillator signals with RSI levels near oversold territory at 30-37.
Investment outlook remains cautious due to incomplete financial data and bearish technical indicators. Rising Treasury yields pose macroeconomic headwinds, while the absence of valuation metrics complicates risk-reward analysis. Investors require updated SEC filings and earnings reports to properly evaluate the company's financial health and growth prospects.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares International Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and will invest at least 90% of its assets in fixed income securities included in the underlying index. The underlying index measures the performance of fixed-rate, local currency, investment-grade, sovereign bonds from certain developed markets. The fund is non-diversified.
Read more on IGOV →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
